Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2015 Oct 6;6(30):30295-305.
doi: 10.18632/oncotarget.4497.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas

Heather E Leeper  1 , Alissa A Caron  2 , Paul A Decker  3 , Robert B Jenkins  4 , Daniel H Lachance  5 , Caterina Giannini  4
Affiliations

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas

Heather E Leeper et al. Oncotarget. .

"VSports app下载" Abstract

Background: Epigenetic, genetic, and molecular studies have identified several diagnostic and prognostic markers in diffuse gliomas VSports手机版. Their importance for evaluating WHO grade II gliomas has yet to be specifically delineated. .

Methods: We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012) V体育安卓版. .

Results: IDHmut was found in 141(91%) and ATRX loss in 64(87%) of IDHmut-noncodel tumors (p = 0. 003). All codeleted tumors (n = 66) were IDHmut. Four subgroups were identified: IDHmut-codel, 66(43%); IDHmut-noncodel-ATRX loss, 60(39%); IDHmut-noncodel-ATRXwt, 9(6%); IDHwt, 14(9%). Median survival among 4 groups was significantly different (p = 0. 038), particularly in IDHmut-codel (median survival 15. 6 years) compared to the remaining 3 groups (p = 0. 025). Survival by histology was not significant. Overall (OS), but not progression-free (PFS), survival was significantly longer with gross total resection vs. biopsy only (p = 0 V体育ios版. 042). Outcomes for patients with subtotal resection were not significantly different from those with biopsy only. Among these uniformly treated patients, OS far exceeds PFS, particularly in those with 1p/19q codeletion. .

Conclusions: For WHO grade II diffuse glioma, molecular classification using 1p/19qcodel, IDHmut, and ATRX loss more accurately predicts outcome and should be incorporated in the neuropathologic evaluation. VSports最新版本.

Keywords: 1p19q codeletion; ATRX; IDH mutation; WHO grade II; diffuse gliomas V体育平台登录. .

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1. Two WHO grade II gliomas are illustrated
The first a. diagnosed as oligoastrocytoma displays infiltration of cortex by a low-density population of cells, in part, with round regular nuclei and clear halos (“oligodendroglial”), in part, with irregular elongated nuclei (“astrocytic”). The cells are IDH1R132H positive b. and lack ATRX expression c. In the second d. diagnosed as oligodendroglioma, tumor cells are IDH1R132H positive e. and maintain ATRX expression f. This second tumor showed 1p19q codeletion by FISH. All photos were taken at 400 × (magnification bar shown in panel a 10 microns).
Figure 2
Figure 2. Low grade diffuse gliomas
Data regarding IDH status, 1p19q codeletion, ATRX status, p53 expression, and histological diagnosis are summarized for all patients (n = 159). Each column represents a patient.
Figure 3
Figure 3. Progression-free and overall survival for all patients
A. PFS for all patients, estimated by Kaplan-Meier method. 5-year PFS: 49.5% (95% CI: 40.6%–60.4%). B. OS for all patients, estimated by Kaplan-Meier method; 5-year OS: 86.2% (95% CI: 79.4%–93.5%)
Figure 4
Figure 4. Progression-free and overall survival by diagnosis and molecular subgroups
A. PFS by histologic diagnosis, estimated by Kaplan-Meier method, p = 0.71. B. OS by histologic diagnosis, estimated by Kaplan-Meier method, p = 0.16. C. PFS by molecular subgroup [IDHmut-codel (n = 65), IDHmut-noncodel-ATRXloss (n = 59), IDHmut-noncodel-ATRXwt (n = 9), IDHwt (n = 14)], estimated by Kaplan-Meier method, p = 0.067. D. OS by molecular subgroup [IDHmut-codel (n = 66), IDHmut-noncodel-ATRXloss (n = 60), IDHmut-noncodel-ATRXwt (n = 9), IDHwt (n = 14)], estimated by Kaplan-Meier method, p = 0.038. All p-values adjust for age, sex, histomorphologic diagnosis, extent of resection, and treatment.
Figure 5
Figure 5. Progression-free and overall survival by extent of resection
A. PFS by extent of resection estimated by Kaplan-Meier method, p = 0.36. B. OS by extent of resection, estimated by Kaplan-Meier method: entire cohort p = 0.12, pairwise GTR vs. biopsy-only: p = 0.042. p-values adjust for age, sex, histomorphologic diagnosis, and treatment.
See this image and copyright information in PMC

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. - PMC - PubMed
    1. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010;120:297–304. - PMC (V体育平台登录) - PubMed
    1. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150–4. - PubMed
    1. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015;372:2499–508. - PMC - PubMed
    1. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481–98. - PMC - PubMed

Publication types

"VSports" MeSH terms